Commercialization Considerations for Cell-Based Therapies: What We Have Learned So Far

AbstractPurpose of ReviewDespite an increasing list of clinically impactful products in cancer, wound care, and graft versus host disease, cellular therapeutics have yet to be fully embraced by large pharma and biotech. While there have been several high-profile investments in the past 5  years, the list of clinically and commercially successful products is still a short one. Here, we highlight some of the critical considerations to increase the likelihood of commercial success.Recent FindingsThe field of Regenerative Medicine is poised to introduce several products that could have profound clinical impact. The recent acquisition of Kite Therapeutics suggests that large pharma sees not only the clinical value but also for the first time, multibillion dollar commercial value.SummaryCell and gene therapies require remarkably long developmental timelines and have complex manufacturing and scaling requirements. Successful commercialization models must accommodate this complex developmental pathway.
Source: Current Transplantation Reports - Category: Transplant Surgery Source Type: research